Source: Rosenkranz, Stephan, and Daniel Dumitrescu. 2017. ‘Pulmonary Hypertension–Back to the Future’. Revista Española de Cardiología (English Edition) 70 (11): 901–4. https://doi.org/10.1016/j.rec.2017.04.008.
Source: Hewes, Jenny L., Ji Young Lee, Karen A. Fagan, and Natalie N. Bauer. ‘The Changing Face of Pulmonary Hypertension Diagnosis: A Historical Perspective on the Influence of Diagnostics and Biomarkers’. Pulmonary Circulation 10, no. 1 (1 January 2020): 2045894019892801. https://doi.org/10.1177/2045894019892801.
imeline of pulmonary arterial hypertension (PAH) registries and their characteristics (list is not exhaustive). Darker circles indicate product registries as opposed to disease registries. PPH: primary pulmonary hypertension; NIH: National Institutes of Health; PHC: Pulmonary Hypertension Connection; IPAH: idiopathic PAH; IPPHS: International Primary Pulmonary Hypertension Study group; TRAX: Tracleer Excellence Post Marketing Surveillance Programme; SPAHR: Swedish Pulmonary Arterial Hypertension Registry; REVEAL: Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension; ASPIRE: Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre; PH: pulmonary hypertension; COMPERA: Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; VOLT: the Volibris Tracking Study; EXPERT: Exposure Registry Riociguat in Patients with Pulmonary Hypertension. *: same mean age in IPAH patients.
Source: Swinnen, Katleen, Rozenn Quarck, Laurent Godinas, Catharina Belge, and Marion Delcroix. ‘Learning from Registries in Pulmonary Arterial Hypertension: Pitfalls and Recommendations’. European Respiratory Review 28, no. 154 (31 December 2019). https://doi.org/10.1183/16000617.0050-2019.
History of PH and development of therapeutic drugs. FDA, U.S. Food and Drug Administration; WHO, World Health Organisation
Source: Sommer, Natascha, Hossein A. Ghofrani, Oleg Pak, Sebastien Bonnet, Steve Provencher, Olivier Sitbon, Stephan Rosenkranz, Marius M. Hoeper, and David G. Kiely. ‘Current and Future Treatments of Pulmonary Arterial Hypertension’. British Journal of Pharmacology 178, no. 1 (2021): 6–30. https://doi.org/10.1111/bph.15016.
Timeline of approval of therapies for pulmonary arterial hypertension. Therapies that are approved in the USA and/or European Union (EU) are included, positioned on the timeline based on the first date of their approval in either USA [2–4] or EU [5]. Therapies are administered orally unless otherwise indicated. ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase-5 inhibitor; sGC: soluble guanylate cyclase; inh: inhaled. #: not approved in the EU.
Source: Gaine, Sean, and Vallerie McLaughlin. 2017. ‘Pulmonary Arterial Hypertension: Tailoring Treatment to Risk in the Current Era’. European Respiratory Review 26 (146). https://doi.org/10.1183/16000617.0095-2017.
October 21, 2023 @ 10:34 pm
This is terrific. It can serve as a foundation for deeper exploration of PVD history.
One minor typo “Groover” should be Grover.